$BRO

Revenue rose 7.4% to $1.7 billion, while profit per share fell 1.5%.

Brown & Brown, Inc. (BRO) reported Q3 2026 revenue growth of 7.4% to $1.7B, but EPS fell 1.5% to $0.67. Net income rose 5.7% to $240M. CEO J. Powell Brown attributed results to team efforts and recent acquisitions. Year-to-date revenue increased 23.4% to $5.3B, with net income up 20.8% to $954M.

Original reporting
Published Oct 26, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BRO
Bearish
high confidence
Mentioned
$BRO
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$BROBearishMed
01

Why it matters

The earnings release provides fresh data on revenue growth and margin pressure, informing short‑term trading decisions.

02

Market read

First‑report earnings for a mid‑cap insurer; relevant for sector and earnings‑focused traders.

03

What to watch

Accretion from the recent Accession acquisition and potential future fee growth are not fully reflected in the current EPS.

Relevance 7/10Novelty 8/10Timing: today

Background

Brown & Brown is a mid‑cap insurance brokerage that recently added ~5,000 employees from Accession.

Company-level read

Ticker impact

$BROBearishHigh confidence
Context

Brown & Brown reported Q3 2026 unaudited results with revenue up 7.4% to $1.7B but diluted EPS down 1.5% to $0.67.

Expected impact

likely downward pressure as market prices in lower EPS despite revenue growth

Evidence & confidence

Revenue growth is solid, but EPS decline signals margin compression; investors typically react negatively to EPS miss.

Market effects

Insurance brokerage sector may see modest scrutiny on margin trends.

U.S. market participants may adjust exposure to mid‑cap insurers.

Limited; primarily affects U.S. listed broker‑insurers.

Counterpoint

Revenue beat could signal upside if the company improves cost control, making the dip in EPS a temporary issue.

Key entities

  • Brown & Brown, Inc.

    Insurance brokerage reporting Q3 2026 results.

Related articles

$BROMed

Brown & Brown Inc (BRO) (Q3 2026) Earnings Call Highlights: Revenue Up 7.4%

Brown & Brown Inc (BRO) reported Q3 2026 revenue up 7.4% to $1.07B, but adjusted EBITDAC margin fell 200 bps to 34.6%. Specialty Distribution organic revenue declined 0.8%, missing expectations due to competition and pricing pressures. The company anticipates further declines in Q4 and faces ongoing litigation impacts. Integration costs for Accession have increased to $250-300M.

$BROMed

What Brown & Brown (BRO) Said on Its Q3 Earnings Call

Brown & Brown (BRO) reported Q3 earnings, noting market shifts in California and Texas, and pricing pressures in commercial earthquake business. The company expects 2027 growth of 2%-4% for retail and 1%-3% for specialty distribution. Accession acquisition raised synergy targets to $50M for 2026 and $175M by 2028. AI initiatives are expanding across the company, with tools like Claude and COMPASS being deployed. The board increased the dividend by 9%.

$BROHighAI 8/10

Brown & Brown (BRO) Q3 2026 Earnings Call Transcript

Brown & Brown (BRO) reported Q3 2026 revenues of $1.7B, up 7.4% YoY. Organic revenue grew 1.2%, while adjusted EBITDAC margin fell 200 bps to 34.6%. Adjusted EPS rose 2% to $1.07. The company raised its dividend by 9%, marking 33 consecutive years of increases. Retail segment outperformed expectations, while specialty distribution faced headwinds. The company repurchased $750M in shares YTD, including $250M in Q3.

$BROMed

Truist cuts Brown & Brown stock price target to $85 on lower estimates

Truist Securities reduced its price target for Brown & Brown (NYSE:BRO) to $85 from $90, citing lower 2026 and 2027 EPS estimates. The firm maintained a Buy rating, basing the target on a 14x multiple of its 2027 EBITDA estimate. BRO's Q3 earnings missed expectations, with revenue at $1.72B and EPS at $1.07, though both showed year-over-year growth. The company's organic growth slowed, and its adjusted EBITDAC margin declined by 200 basis points.

$BROMed

Why Brown & Brown (BRO) stock is trading lower today

Brown & Brown (BRO) shares fell 4.9% after reporting Q3 2026 revenue of $1.73B, up 7.4% YoY, but with slowing organic growth and margin compression. CEO Powell Brown noted declines in excess-and-surplus property rates and expected further decreases in 2027. The stock is down 13.4% YTD, trading at $67.25, 23.4% below its 52-week high.